IL235991A - Phenyl triazole sequestration and its use in modulating the gabaa receptor complex - Google Patents

Phenyl triazole sequestration and its use in modulating the gabaa receptor complex

Info

Publication number
IL235991A
IL235991A IL235991A IL23599114A IL235991A IL 235991 A IL235991 A IL 235991A IL 235991 A IL235991 A IL 235991A IL 23599114 A IL23599114 A IL 23599114A IL 235991 A IL235991 A IL 235991A
Authority
IL
Israel
Prior art keywords
modulating
receptor complex
triazole derivative
gabaa receptor
phenyl triazole
Prior art date
Application number
IL235991A
Other languages
English (en)
Hebrew (he)
Other versions
IL235991A0 (en
Original Assignee
Saniona Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saniona Aps filed Critical Saniona Aps
Publication of IL235991A0 publication Critical patent/IL235991A0/en
Publication of IL235991A publication Critical patent/IL235991A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL235991A 2012-06-26 2014-11-30 Phenyl triazole sequestration and its use in modulating the gabaa receptor complex IL235991A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261664288P 2012-06-26 2012-06-26
DKPA201270369 2012-06-26
PCT/EP2013/063194 WO2014001282A1 (en) 2012-06-26 2013-06-25 A phenyl triazole derivative and its use for modulating the gabaa receptor complex

Publications (2)

Publication Number Publication Date
IL235991A0 IL235991A0 (en) 2015-02-01
IL235991A true IL235991A (en) 2017-07-31

Family

ID=49782300

Family Applications (1)

Application Number Title Priority Date Filing Date
IL235991A IL235991A (en) 2012-06-26 2014-11-30 Phenyl triazole sequestration and its use in modulating the gabaa receptor complex

Country Status (13)

Country Link
US (2) US9475797B2 (OSRAM)
EP (1) EP2885290B1 (OSRAM)
JP (1) JP6223443B2 (OSRAM)
KR (1) KR20150033679A (OSRAM)
CN (1) CN104411703A (OSRAM)
AU (1) AU2013283488A1 (OSRAM)
BR (1) BR112014032501A2 (OSRAM)
CA (1) CA2876780A1 (OSRAM)
IL (1) IL235991A (OSRAM)
IN (1) IN2014DN11027A (OSRAM)
MX (1) MX2014014872A (OSRAM)
RU (1) RU2014149123A (OSRAM)
WO (1) WO2014001282A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102019014802A2 (pt) * 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
IL296716A (en) 2020-03-26 2022-11-01 Richter Gedeon Nyrt History of naphthyridine and pyrido[4,3-c]pyridazine as gabaa alpha 5 receptor modulators
EP4149933B1 (en) * 2020-05-13 2024-06-12 F. Hoffmann-La Roche AG New triazolyl derivatives as gaba a alpha5 pam
EP3992188A1 (en) * 2020-10-29 2022-05-04 Boehringer Ingelheim International GmbH Difluoromethyl-pyridin-2-yl triazoles
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
CN116462664B (zh) * 2022-03-08 2025-07-01 上海赛默罗生物科技有限公司 吡唑环类化合物、其制备方法、组合物及应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0874846B1 (en) 1995-11-01 2003-04-02 Novartis AG Purine derivatives and processes for their preparation
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
CA2314401A1 (en) 1997-12-22 1999-07-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE60028253T2 (de) 1999-12-17 2007-03-08 Ariad Pharmaceuticals, Inc., Cambridge Neue purine
IL150061A0 (en) 1999-12-17 2002-12-01 Ariad Pharma Inc Purine derivatives
US7115589B2 (en) 1999-12-17 2006-10-03 Ariad Pharmaceuticals, Inc. Purine derivatives
DE60205376T2 (de) 2001-06-27 2006-04-06 Cyclacel Ltd. 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
US7262176B2 (en) 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
CA2463563A1 (en) 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
US20060009642A1 (en) 2001-10-12 2006-01-12 Irm Llc, A Delaware Limited Liability Company Methods for the synthesis of substituted purines
US20030229105A1 (en) 2002-05-21 2003-12-11 Cyclacel Limited Treatment of autoimmune disorders
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
JP2006503826A (ja) 2002-09-06 2006-02-02 スミスクライン・ビーチャム・コーポレイション ピロロ［２，３−ｄ］ピリミジン−４−イルおよびプリン−６−イル尿素化合物
MXPA06001758A (es) 2003-08-15 2006-08-11 Irm Llc Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk.
US20050187389A1 (en) 2004-01-13 2005-08-25 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2005080377A1 (ja) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
GB0407723D0 (en) 2004-04-05 2004-05-12 Novartis Ag Organic compounds
FR2876583B1 (fr) 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
US8252806B2 (en) 2005-03-14 2012-08-28 Neurosearch A/S Potassium channel modulating agents and their medical use
GB0505219D0 (en) 2005-03-14 2005-04-20 Novartis Ag Organic compounds
US20090036475A1 (en) 2005-03-22 2009-02-05 Neurosearch A/S Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use
CA2609117A1 (en) 2005-05-19 2006-11-23 Cv Therapeutics, Inc. A1 adenosine receptor agonists
KR100976675B1 (ko) 2005-09-19 2010-08-18 에프. 호프만-라 로슈 아게 Ｇａｂａ ａ 알파5 역작용물질로서의 아이속사졸로 유도체
AU2006301376A1 (en) 2005-10-11 2007-04-19 F. Hoffmann-La Roche Ag Isoxazole derivatives
EP1948648B1 (en) 2005-11-09 2010-05-05 F.Hoffmann-La Roche Ag 3-aryl-isoxazole-4-carbonyl-benzofurane derivatives
EP1966184B1 (en) 2005-12-20 2010-08-25 NeuroSearch A/S Pyridinyl-quinazoline derivatives and their medical use
ES2397401T3 (es) 2005-12-23 2013-03-06 F. Hoffmann-La Roche Ag Derivados de aril-isoxazol-4-il-oxadiazol
US7399769B2 (en) 2005-12-27 2008-07-15 Hoffmann-La Roche Inc. Aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives
CA2633367A1 (en) 2005-12-27 2007-07-05 F. Hoffmann-La Roche Ag Aryl-isoxazol-4-yl-imidazole derivatives
EP2029558B1 (en) * 2006-05-24 2010-03-10 Eli Lilly And Company Compounds and methods for modulating fxr
WO2007137954A1 (en) 2006-05-31 2007-12-06 F. Hoffmann-La Roche Ag Aryl-4-ethynyl-isoxazole derivatives
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
JP2010502674A (ja) 2006-09-07 2010-01-28 ノイロサーチ アクティーゼルスカブ カリウムチャンネル調節剤として有用なピリジニル−ピリミジン誘導体
CA2665398A1 (en) 2006-10-03 2008-04-10 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
KR20090112732A (ko) 2007-01-26 2009-10-28 아이알엠 엘엘씨 플라스모듐 관련 질환의 치료를 위한 키나제 억제제로서의 퓨린 화합물 및 조성물
JP2010517970A (ja) 2007-02-02 2010-05-27 ノイロサーチ アクティーゼルスカブ ピリジニル−ピラゾール誘導体及びカリウムチャネル調節剤としてのそれらの使用
KR101564233B1 (ko) 2007-03-28 2015-10-29 뉴로서치 에이/에스 푸리닐 유도체 및 칼륨 채널 조절제로서의 이의 용도
EP2142545A1 (en) 2007-03-28 2010-01-13 NeuroSearch A/S Purinyl derivatives and their use as potassium channel modulators
ATE519760T1 (de) 2007-06-22 2011-08-15 Hoffmann La Roche Isoxazolimidazolderivate
CA2703039A1 (en) 2007-10-17 2009-04-23 Novartis Ag Purine derivatives as adenosine a1 receptor ligands
US7943619B2 (en) * 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
AU2008333320B2 (en) 2007-12-04 2012-12-20 F. Hoffmann-La Roche Ag Isoxazolo-pyrazine derivatives
HUE025545T2 (en) 2007-12-04 2016-03-29 Hoffmann La Roche Isoxazole-pyridine derivatives
EP2128158A1 (en) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
PE20140858A1 (es) * 2008-06-19 2014-08-04 Takeda Pharmaceutical Derivados de piperidina como inhibidores de renina
US8268838B2 (en) 2008-09-26 2012-09-18 Neurosearch A/S Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators
WO2010034706A1 (en) 2008-09-26 2010-04-01 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US20100280019A1 (en) 2009-04-30 2010-11-04 Roland Jakob-Roetne Isoxazoles
MX2011011477A (es) 2009-05-05 2011-11-18 Hoffmann La Roche Derivados de isoxazol-piridazina.
WO2010127976A1 (en) 2009-05-05 2010-11-11 F. Hoffmann-La Roche Ag Isoxazole-pyridine derivatives
SG175869A1 (en) 2009-05-05 2011-12-29 Hoffmann La Roche Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders
MX2011011273A (es) 2009-05-05 2011-11-04 Hoffmann La Roche Derivados de isoxazol-pirazol.
SG175318A1 (en) 2009-05-07 2011-11-28 Hoffmann La Roche Isoxazole-pyridine derivatives as gaba modulators
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US8742097B2 (en) * 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
WO2012062623A1 (en) * 2010-11-09 2012-05-18 F. Hoffmann-La Roche Ag Triazole derivatives as ligands for gaba receptors
US8466181B2 (en) 2010-12-10 2013-06-18 Hoffmann-La Roche Inc. 1,2,3-triazole-imidazole compounds

Also Published As

Publication number Publication date
US9884848B2 (en) 2018-02-06
WO2014001282A1 (en) 2014-01-03
EP2885290B1 (en) 2017-10-18
US20170114045A1 (en) 2017-04-27
JP2015521643A (ja) 2015-07-30
EP2885290A1 (en) 2015-06-24
MX2014014872A (es) 2015-08-06
KR20150033679A (ko) 2015-04-01
RU2014149123A (ru) 2016-08-20
CN104411703A (zh) 2015-03-11
BR112014032501A2 (pt) 2017-06-27
IN2014DN11027A (OSRAM) 2015-09-25
AU2013283488A1 (en) 2015-01-15
CA2876780A1 (en) 2014-01-03
US20160115155A1 (en) 2016-04-28
JP6223443B2 (ja) 2017-11-01
US9475797B2 (en) 2016-10-25
IL235991A0 (en) 2015-02-01

Similar Documents

Publication Publication Date Title
GB201304182D0 (en) No details
GB201403961D0 (en) No details
EP2717649A4 (en) HEATING ELEMENT
IL236041A0 (en) A consequence of phenyltriazole and its use to modulate the gabaa receptor complex
GB201209880D0 (en) Applicators
EP2853105A4 (en) CONTROLLED SEARCH
GB201411220D0 (en) No details
IL235991A (en) Phenyl triazole sequestration and its use in modulating the gabaa receptor complex
EP2626648B8 (en) Space heater
PL2631584T3 (pl) Grzejnik
GB2518990B (en) Controls
GB201313844D0 (en) No details
GB201403415D0 (en) No details
GB201220529D0 (en) No details available
GB201221454D0 (en) The scunthorpe urine flowstix holster
AU5123P (en) Sprilecstar Cordyline banksii
GB201211308D0 (en) Compounds for use
AU344966S (en) Sideboard
GB201206013D0 (en) The easy fix hinge
GB201322955D0 (en) No details
GB201400108D0 (en) No details
GB201206393D0 (en) Use
GB201302155D0 (en) No details
GB201300109D0 (en) No details
GB201310646D0 (en) No details

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees